HC Wainwright Analysts Decrease Earnings Estimates for COYA

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at HC Wainwright dropped their Q1 2026 earnings per share estimates for Coya Therapeutics in a research report issued to clients and investors on Monday, March 23rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.39) per share for the quarter, down from their prior estimate of ($0.33). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($1.64) EPS.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. D. Boral Capital restated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Monday, March 16th. Finally, Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Stock Performance

COYA stock opened at $4.15 on Wednesday. The firm has a fifty day moving average price of $4.67 and a 200 day moving average price of $5.48. Coya Therapeutics has a fifty-two week low of $3.94 and a fifty-two week high of $7.75. The firm has a market cap of $97.36 million, a PE ratio of -3.27 and a beta of 0.23.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). The firm had revenue of $3.96 million during the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.

Institutional Trading of Coya Therapeutics

Institutional investors have recently bought and sold shares of the stock. Alyeska Investment Group L.P. purchased a new position in Coya Therapeutics during the fourth quarter worth $4,640,000. AWM Investment Company Inc. purchased a new stake in shares of Coya Therapeutics in the fourth quarter valued at $4,205,000. Private Management Group Inc. purchased a new stake in shares of Coya Therapeutics in the fourth quarter valued at $1,626,000. Marshall Wace LLP lifted its holdings in shares of Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after acquiring an additional 183,533 shares during the last quarter. Finally, Dauntless Investment Group LLC lifted its holdings in shares of Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after acquiring an additional 101,932 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors.

Key Stories Impacting Coya Therapeutics

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a high $18.00 price target, and its analyst published FY2027 and quarterly EPS forecasts that anticipate continued investment in the pipeline — this bullish research likely supports investor interest in COYA’s long‑term upside. TipRanks: H.C. Wainwright reiterates Buy
• Neutral Sentiment: Multiple reports show a “large increase” in short interest for March, but the published short-interest totals are zero (and days-to-cover ratios are 0.0), indicating the short-interest data is anomalous/likely erroneous — not a clear driver of price action today.
• Negative Sentiment: Recent quarterly results (reported March 16) showed an EPS miss (reported -$0.34 vs. consensus -$0.08) and continued negative margins and ROE, which keep near-term fundamentals pressured and can blunt enthusiasm from bullish analyst notes.
• Negative Sentiment: Technical and trading context is unfavorable: the stock is below its 50‑day ($4.68) and 200‑day ($5.50) moving averages and near its 52‑week low, and intraday volume is below average — factors that can contribute to downward price pressure despite positive coverage.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.